vs

Side-by-side financial comparison of Bristol Myers Squibb (BMY) and Ingram Micro Holding Corp (INGM). Click either name above to swap in a different company.

Ingram Micro Holding Corp is the larger business by last-quarter revenue ($14.0B vs $11.5B, roughly 1.2× Bristol Myers Squibb). Bristol Myers Squibb runs the higher net margin — 23.3% vs 0.7%, a 22.6% gap on every dollar of revenue. On growth, Ingram Micro Holding Corp posted the faster year-over-year revenue change (13.7% vs 11.0%). Over the past eight quarters, Ingram Micro Holding Corp's revenue compounded faster (11.0% CAGR vs -3.0%).

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...

Ingram Micro Holding Corporation is an American distributor of information technology products and services. The company is based in Irvine, California, U.S. and has operations around the world. Founded as Micro D, Inc in 1979 in California by Geza Czige and Lorraine Mecca, the company, originally a traditional distributor focused on marketing, selling and shipping vendor products to resellers, is currently specializing on becoming a platform-based business that focuses on its digital experie...

BMY vs INGM — Head-to-Head

Bigger by revenue
INGM
INGM
1.2× larger
INGM
$14.0B
$11.5B
BMY
Growing faster (revenue YoY)
INGM
INGM
+2.7% gap
INGM
13.7%
11.0%
BMY
Higher net margin
BMY
BMY
22.6% more per $
BMY
23.3%
0.7%
INGM
Faster 2-yr revenue CAGR
INGM
INGM
Annualised
INGM
11.0%
-3.0%
BMY

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BMY
BMY
INGM
INGM
Revenue
$11.5B
$14.0B
Net Profit
$2.7B
$98.9M
Gross Margin
6.6%
Operating Margin
1.6%
Net Margin
23.3%
0.7%
Revenue YoY
11.0%
13.7%
Net Profit YoY
8.8%
42.9%
EPS (diluted)
$0.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BMY
BMY
INGM
INGM
Q1 26
$11.5B
$14.0B
Q4 25
$12.5B
$14.9B
Q3 25
$12.2B
$12.6B
Q2 25
$12.3B
$12.8B
Q1 25
$11.2B
$12.3B
Q4 24
$12.3B
Q3 24
$11.9B
$11.8B
Q2 24
$12.2B
$11.5B
Net Profit
BMY
BMY
INGM
INGM
Q1 26
$2.7B
$98.9M
Q4 25
$1.1B
$121.4M
Q3 25
$2.2B
$99.5M
Q2 25
$1.3B
$37.8M
Q1 25
$2.5B
$69.2M
Q4 24
$72.0M
Q3 24
$1.2B
$77.0M
Q2 24
$1.7B
$54.6M
Gross Margin
BMY
BMY
INGM
INGM
Q1 26
6.6%
Q4 25
67.2%
6.5%
Q3 25
71.9%
6.9%
Q2 25
72.5%
6.6%
Q1 25
72.9%
6.7%
Q4 24
61.0%
Q3 24
75.1%
7.2%
Q2 24
73.2%
7.2%
Operating Margin
BMY
BMY
INGM
INGM
Q1 26
1.6%
Q4 25
11.8%
2.1%
Q3 25
25.5%
1.8%
Q2 25
14.5%
1.1%
Q1 25
26.5%
1.6%
Q4 24
1.4%
Q3 24
14.1%
1.9%
Q2 24
10.5%
1.6%
Net Margin
BMY
BMY
INGM
INGM
Q1 26
23.3%
0.7%
Q4 25
8.7%
0.8%
Q3 25
18.0%
0.8%
Q2 25
10.7%
0.3%
Q1 25
21.9%
0.6%
Q4 24
0.6%
Q3 24
10.2%
0.7%
Q2 24
13.8%
0.5%
EPS (diluted)
BMY
BMY
INGM
INGM
Q1 26
$0.68
Q4 25
$0.54
$0.52
Q3 25
$1.08
$0.42
Q2 25
$0.64
$0.16
Q1 25
$1.20
$0.29
Q4 24
$0.05
Q3 24
$0.60
$0.35
Q2 24
$0.83
$0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BMY
BMY
INGM
INGM
Cash + ST InvestmentsLiquidity on hand
$9.6B
$916.0M
Total DebtLower is stronger
$-42.2B
$3.3B
Stockholders' EquityBook value
$4.2B
Total Assets
$20.9B
Debt / EquityLower = less leverage
0.79×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BMY
BMY
INGM
INGM
Q1 26
$9.6B
$916.0M
Q4 25
$10.2B
$1.9B
Q3 25
$15.7B
$802.6M
Q2 25
$12.6B
$856.7M
Q1 25
$10.9B
$881.6M
Q4 24
$10.3B
Q3 24
$7.9B
$849.5M
Q2 24
$6.3B
Total Debt
BMY
BMY
INGM
INGM
Q1 26
$-42.2B
$3.3B
Q4 25
$44.8B
$3.2B
Q3 25
$48.7B
$3.8B
Q2 25
$48.9B
$3.7B
Q1 25
$49.5B
$3.5B
Q4 24
$49.4B
Q3 24
$49.5B
$3.8B
Q2 24
$52.0B
Stockholders' Equity
BMY
BMY
INGM
INGM
Q1 26
$4.2B
Q4 25
$18.5B
$4.2B
Q3 25
$18.6B
$4.1B
Q2 25
$17.4B
$4.0B
Q1 25
$17.4B
$3.9B
Q4 24
$16.3B
Q3 24
$17.1B
$3.6B
Q2 24
$17.0B
$3.5B
Total Assets
BMY
BMY
INGM
INGM
Q1 26
$20.9B
Q4 25
$90.0B
$21.2B
Q3 25
$96.9B
$19.2B
Q2 25
$94.7B
$19.5B
Q1 25
$92.4B
$18.6B
Q4 24
$92.6B
Q3 24
$93.7B
$18.6B
Q2 24
$94.6B
Debt / Equity
BMY
BMY
INGM
INGM
Q1 26
0.79×
Q4 25
2.43×
0.75×
Q3 25
2.63×
0.93×
Q2 25
2.81×
0.92×
Q1 25
2.85×
0.90×
Q4 24
3.03×
Q3 24
2.89×
1.06×
Q2 24
3.05×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BMY
BMY
INGM
INGM
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$-962.3M
FCF MarginFCF / Revenue
-6.9%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$53.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BMY
BMY
INGM
INGM
Q1 26
Q4 25
$2.0B
$1.6B
Q3 25
$6.3B
$-146.0M
Q2 25
$3.9B
$-298.0M
Q1 25
$2.0B
$-200.4M
Q4 24
$4.4B
Q3 24
$5.6B
$-277.0M
Q2 24
$2.3B
Free Cash Flow
BMY
BMY
INGM
INGM
Q1 26
$-962.3M
Q4 25
$1.6B
$1.5B
Q3 25
$6.0B
$-175.0M
Q2 25
$3.6B
$-333.2M
Q1 25
$1.7B
$-230.2M
Q4 24
$4.1B
Q3 24
$5.3B
$-315.0M
Q2 24
$2.1B
FCF Margin
BMY
BMY
INGM
INGM
Q1 26
-6.9%
Q4 25
12.8%
10.2%
Q3 25
49.0%
-1.4%
Q2 25
29.0%
-2.6%
Q1 25
15.1%
-1.9%
Q4 24
32.9%
Q3 24
44.3%
-2.7%
Q2 24
16.9%
Capex Intensity
BMY
BMY
INGM
INGM
Q1 26
0.3%
Q4 25
3.0%
0.2%
Q3 25
2.6%
0.2%
Q2 25
2.9%
0.3%
Q1 25
2.3%
0.2%
Q4 24
3.1%
Q3 24
2.7%
0.3%
Q2 24
2.1%
Cash Conversion
BMY
BMY
INGM
INGM
Q1 26
Q4 25
1.82×
12.85×
Q3 25
2.87×
-1.47×
Q2 25
2.99×
-7.88×
Q1 25
0.80×
-2.90×
Q4 24
61.65×
Q3 24
4.62×
-3.60×
Q2 24
1.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons